Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider is now Schiff

This article was originally published in The Tan Sheet

Executive Summary

Weider Nutrition International formally changes name to Schiff Nutrition International following a shareholder vote of approval Oct. 25, the firm announces. "The Schiff brand is a recognized premium brand in the nutritional supplements arena, and it is appropriate that our new corporate name reflects our strategic commitment to growing the Schiff brand," President and CEO Bruce Wood said. The firm divested the Weider brand business last year, and its European subsidiary Haleko in June (1"The Tan Sheet" Aug. 23, 2004, p. 12 and 2"The Tan Sheet" June 27, 2005, In Brief). While the firm will start trading on the New York Stock exchange under the new name Nov. 1, WNI will remain the company's N.Y. Stock Exchange symbol....

You may also be interested in...



Follow The Weider: Analysts Glance Askance At Weider Brand Sale

Weider Nutrition International's sale of its namesake branded nutritionals to the company's majority stockholder is raising some concerns in the investment community

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel